Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Findings from a,trial of the accuracy of CT ... pre-cancerous polyps and colorectal cancers,coordinated by the American ... issues for the public about colorectal cancer,screening using ... need for follow-up,with complete colonoscopy in many cases, ...
... The Department of,Justice announced today that it will ... Cancer (CRC) to develop and publicize model contract ... The Department said,the language is not likely to ... efficiency in contract negotiations, potentially reducing costs,and shortening ...
Cached Medicine Technology:Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 2Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 3Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- A large influx ... Africa is to avoid tens of thousands of deaths ... University researchers predict. Using a specially designed ... of the outbreak in just one densely populated county ... capital city of Monrovia. The researchers said that ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... ... to the position of Chief Operating Officer. She brings to the position more than ... business process review, performance management, organizational development, and quality assurance. , ... Columbus, OH (Vocus) September 11, 2009 ...
... , , , , ... costs are the single biggest economic concern facing American businesses, according to ... , Nearly 90% of those polled cite health care costs ... or energy costs. , , Without reform, 86% of ...
... from electronic assistance, researchers say , FRIDAY, Sept. 11 ... people can, new research suggests. , The findings may ... hard-of-hearing learn to read lips, according to researchers from ... compared the accuracy of an automated lip-reading machine to ...
... Reducing Americans, average intake of sodium to the amount recommended ... $18 billion annually in avoided health care costs and improve ... a new RAND Corporation study. The study estimates that ... high blood pressure nationally and extend the lives of thousands ...
... Sept. 11 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... partner, has informed the company that Reme-Flu(TM) has been ... for helping to prevent and treat flu-like symptoms resulting ... consists of a two-part protocol. Part one contains ...
... , , MISSISSAUGA, Ontario, Sept. 11 ... into an agreement with The Investor Relations Group, Inc. ("IRG"), pursuant ... services for the Company in accordance with the terms of the ... inquiries directly to IRG. , , "We are ...
Cached Medicine News:Health News:CBCA Administrators, Inc. Promotes Cindy Sonnen to Chief Operating Officer 2Health News:Poll Shows Solid Business Support for Health Care Reform 2Health News:Poll Shows Solid Business Support for Health Care Reform 3Health News:Computers Might Make Learning Lip Reading Easier 2Health News:Lowering sodium consumption could save US $18 billion annually in health costs, study finds 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 3Health News:JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc. 2
The soft silicone design promotes patient comfort. , ,Bivona® laryngectomy tubes feature a soft compliant silicone design for patient comfort....
Manufactured with a radiopaque line running down the length of the tube, position can be easily visualized by x-ray....
... vertical length tubes are often indicated ... stenosis, and tracheal malacia. Available in ... two independently inflatable cuffs. Greater flexibility ... since cuff sites can be alternated, ...
... It has been estimated that in excess ... special needs that require a specialized tracheostomy ... Tubes are soft, flexible, and can adapt ... patient including those requiring:, extra horizontal ...
Medicine Products: